[Cholestatic síndrome due to labetalol].
Vicuña-Arregui
M
M
Ruiz-Clavijo-García
D
D
Zozaya-Urmeneta
J M
JM
Bolado-Concejo
F
F
Nantes-Castillejo
O
O
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D001017:Aortic Coarctation / Q000150:complications / Q000188:drug therapy; D001778:Blood Coagulation Disorders / Q000139:chemically induced / Q000150:complications; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology*; D002779:Cholestasis / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D007741:Labetalol / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male
D000319:Adrenergic beta-Antagonists; D007741:Labetalol